Valsartan
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00177 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 18 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | malignant hypertensive renal disease | KG + DL |
| 2 | malignant renovascular hypertension | KG + DL |
| 3 | pulmonary hypertension with unclear multifactorial mechanism | KG + DL |
| 4 | pulmonary hypertension owing to lung disease and/or hypoxia | KG + DL |
| 5 | Braddock syndrome | KG + DL |
| 6 | chronic pulmonary heart disease | KG + DL |
| 7 | Prinzmetal angina | KG + DL |
| 8 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 9 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 10 | obsolete susceptibility to ischemic stroke | KG + DL |
| 11 | intracerebral hemorrhage | KG + DL |
| 12 | brain stem infarction | KG + DL |
| 13 | cerebrovascular disorder | KG + DL |
| 14 | diabetic nephropathy | KG + DL |
| 15 | ABri amyloidosis | KG + DL |
| 16 | cerebral artery occlusion | KG + DL |
| 17 | cerebral infarction | KG + DL |
| 18 | MRI defined brain infarct | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.